2 Growth Stocks Poised to Outperform the Market Through 2031

In an era defined by rapid technological advancement and evolving healthcare needs, investors seeking long-term outperformance must gravitate toward companies that combine innovation with scalable market opportunities. Two such names-Eli Lilly and Alphabet-stand out as compelling candidates. While Eli Lilly is revolutionizing the obesity treatment landscape with its GLP-1 pipeline, Alphabet is leveraging AI and cloud computing to redefine enterprise technology. Together, they represent a powerful duality of pharmaceutical and tech-driven growth, offering a balanced approach to capturing the most transformative trends of the next decade.

Eli Lilly: Dominating the Obesity Market with a Blockbuster Pipeline

Eli Lilly's third-quarter 2025 results underscore its meteoric rise as a pharmaceutical leader. Revenue surged 54% year-over-year to $17.6 billion, driven by the blockbuster performance of Mounjaro and Zepbound, which generated over $10 billion in a single quarter according to financial results. The company raised its full-year revenue guidance to $63–63.5 billion, reflecting confidence in sustained demand for its GLP-1 therapies.

Beyond near-term success, Lilly's pipeline is a masterclass in strategic innovation. Orforglipron, an oral GLP-1 receptor agonist, is set to become a game-changer. With positive Phase 3 trial results for type 2 diabetes and obesity, Lilly plans to submit it for regulatory approval by year-end 2025 according to the company's announcement. Analysts project orforglipron could generate $13 billion in annual sales by 2031, capitalizing on the obesity market's projected $200 billion valuation by 2031 according to market research.

Equally promising is retatrutide, a triple hormone agonist targeting GLP-1, GIP, and glucagon receptors. In clinical trials, it achieved a 24.2% average weight loss-surpassing existing therapies like tirzepatide. With late-stage trial data expected in 2025 and a potential 2026–2027 launch, retatrutide could solidify Lilly's dominance in a market where it already holds a 44% share.

Lilly's competitive edge extends beyond drugs. The company is investing $93 billion in 2025 capital expenditures to expand manufacturing in the U.S. and Puerto Rico, while also deploying AI-driven supercomputers to accelerate drug discovery. These moves position it to maintain leadership even as 16 new obesity drugs enter the market by 2029. Analysts project a $2 trillion market cap by 2031, fueled by a 12.3% compound annual growth rate.

Alphabet: Building an AI-First Future

While Eli Lilly thrives in biotech, Alphabet is reshaping the tech landscape through AI and cloud computing. In Q3 2025, Google Cloud revenue hit $15.2 billion, up 34% year-over-year, with operating income surging 85% to $3.6 billion. The segment's $155 billion backlog signals multi-year demand, as enterprises increasingly rely on AI infrastructure.

Alphabet's AI ambitions are equally transformative. The Gemini 3 model and AI Overviews have revitalized Google Search, while Tensor Processing Units (TPUs) are enabling generative AI breakthroughs. With 85,000 enterprise customers now using Gemini, Alphabet is closing the gap with Amazon and Microsoft in cloud market share (13% in Q3 2025).

Long-term projections are equally bullish. The U.S. cloud market is expected to grow from $221.69 billion in 2024 to $871.61 billion by 2033, with AI-driven demand accelerating this trajectory. Alphabet's $91–93 billion 2025 capital spending plan and its $3.35 trillion market cap as of November 2025 reflect its commitment to capturing this growth. Analysts predict a $5 trillion market cap by 2026 and a stock price of $572.64 by 2030 according to financial projections, driven by AI's potential to surpass cloud computing's $2.3–2.6 trillion market size by 2030 according to market analysis.

A Diversified Growth Thesis for 2031

Eli Lilly and Alphabet represent two sides of the same coin: one addressing a global health crisis with life-changing therapies, the other enabling the digital infrastructure underpinning the AI revolution. Lilly's obesity treatments are poised to benefit from a $173.5 billion market in seven major economies by 2031, while Alphabet's cloud and AI segments are set to capitalize on a $1.8 trillion AI market.

For investors, the synergy is clear. Lilly's high-margin pharmaceuticals offer predictable cash flows and regulatory tailwinds, while Alphabet's tech-driven diversification provides exposure to exponential growth in AI and enterprise software. Together, they form a resilient portfolio capable of weathering macroeconomic volatility while outperforming through 2031.

###